

## Latisse® (bimatoprost) – First-Time Generic

- On December 7, 2016, <u>Sandoz announced</u> the launch of its <u>AT-rated</u> generic version of Allergan's <u>Latisse</u> (<u>bimatoprost</u>) 0.03% ophthalmic solution, to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.
- Bimatoprost is also available as <u>Lumigan<sup>®</sup></u>, for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
  - Lumigan is available generically as a 0.03% ophthalmic solution and as a branded 0.01% product.
- According to IMS Health, U.S. sales for Latisse were approximately \$75 million for the 12 month period ending in October 2016.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.